Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rusal registered a new holding company in Qatar for foreign assets

6/30/23 RUAL

Virgin Galactic has successfully flown its first commercial flight into space

6/30/23 SPCE

Whoosh is exploring the possibility of entering three countries in South America

6/30/23 WUSH

The AT&T announced a quarterly dividend

6/30/23 T

Nike reported for fiscal year 2023

6/30/23 NKE

VK launched a beta version of the "VK Dating" app

6/29/23 VKCO

Cherkizovo plans to supply products to Malaysia

6/29/23 GCHE

Shareholders of European Eltech approved dividends for 2022

6/29/23 EELT

The Worthington Industries announced a quarterly dividend

6/29/23 WOR

The Micron Technology announced a quarterly dividend

6/29/23 MU